Direct antiproliferative effect of nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors <i>in vitro</i>

Berényi, Ágnes; Frotscher, Martin; Marchais‐Oberwinkler, Sandrine; Hartmann, Rolf W.; Minorics, Renáta; Ocsovszki, Imre; Falkay, George; Zupkó, István

doi:10.3109/14756366.2012.672414

Search citation statements

Order By: Relevance

Paper Sections

Select...

Figure1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some members of this inhibitor class, e.g. compounds 37a and 37b, were reported to exert direct antiproliferative activity in vitro in cancer cell lines by influencing the cell cycle (Berenyi et al 2013). Nonsteroidal inhibitors of 17β-HSD1: Bis(hydroxyphenyl) substituted arenes.…”

Section: Figurementioning

confidence: 99%

Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges

Salah

Abdelsamie²,

Frotscher

2019

Molecular and Cellular Endocrinology

Self Cite

View full text Add to dashboard Cite

During the past 25 years, the modulation of estrogen action by inhibition of 17β-hydroxysteroid dehydrogenase types 1 and 2 (17β-HSD1 and 17β-HSD2), respectively, has been pursued intensively. In the search for novel treatment options for estrogen-dependent diseases (EDD) and in order to explore estrogenic signaling pathways, a large number of steroidal and nonsteroidal inhibitors of these enzymes has been described in the literature. The present review gives a survey on the development of inhibitor classes as well as the structural formulas and properties of their most interesting representatives. In addition, rationally designed dual inhibitors of both 17β-HSD1 and steroid sulfatase (STS) as well as the first inhibitors of 17β-HSD14 are covered.

show abstract

Section: Figurementioning

confidence: 99%